Open an account

Enveric Biosciences

ENVB · NASDAQ

$1.44+$0.05 (+3.60%)TodayMarket closed ·
Prev close $1.39

About ENVB

Enveric Biosciences, Inc. is a biotechnology company which engages in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company is headquartered in Cambridge, Massachusetts and currently employs 5 full-time employees. The company went IPO on 2009-07-21. The firm is engaged in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its discovery and development platform, the Psybrary platform, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, the Company seeks to develop a robust intellectual property portfolio of drug candidates. Its lead molecule, EB-003, is a neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. The firm is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing other Psybrary platform drug candidates to third-party licensees and advancing non-competitive market strategies for patient care.

Employees
6
Headquarters
Cambridge, Massachusetts
Listed
Jul 21, 2009
Sector
Health Care
Industry
Pharmaceuticals
Website
enveric.com

ENVB key statistics

Market cap
6.45M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
65.61K
Volume
31.41K
Open price
$1.40
High today
$1.45
Low today
$1.38
52 Week high
$13.25
52 Week low
$1.17

Enveric Biosciences (ENVB) at a glance

Enveric Biosciences (ENVB) last traded at $1.44, with a market cap of 6.45M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.38 and $1.45. The current price is 4.7% above the day's low and 0.3% below its high.

Volume so far is 31.41K shares, below the average of 65.61K shares a day.

Over the past year Enveric Biosciences has ranged from $1.17 to $13.25, and now sits 2% of the way up that range.

Enveric Biosciences met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q4 FY24 it reported -$57.60 per share against an estimate of -$2.82.

ENVB earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 36.4% on average.

  1. Q3 FY22: reported -$444.60 per share against an estimate of -$734.40
  2. Q2 FY23: reported -$547.20 per share against an estimate of -$119.34
  3. Q3 FY23: reported -$234.00 per share against an estimate of -$383.72
  4. Q4 FY23: reported -$264.60 per share against an estimate of -$283.66
  5. Q1 FY24: reported -$109.80 per share against an estimate of -$142.29
  6. Q2 FY24: reported -$45.00 per share against an estimate of -$100.98
  7. Q3 FY24: reported -$43.20 per share against an estimate of -$95.47
  8. Q4 FY24: reported -$57.60 per share against an estimate of -$2.82

ENVB news

  • Press releaseBusiness Wire

    Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

  • Press releaseBusiness Wire

    Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference

  • Press releaseBusiness Wire

    Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026

  • Vandana Singh

    Enveric Biosciences Says New Preclinical Data Confirms Non-Hallucinogenic Profile For Lead Psychiatric Candidate

  • Press releaseBusiness Wire

    Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003

  • Press releaseBusiness Wire

    Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development

  • Press releaseBusiness Wire

    Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit

  • Press releaseBusiness Wire

    Enveric Biosciences Announces Participation in 2026 BIO International Convention

Similar companies

Companies in the same industry as Enveric Biosciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.